MD Anderson researchers developed GT19630, a first-in-class dual-degrader targeting MYC and GSPT1, showing potent preclinical activity in blood cancers including treatment-resistant and TP53-mutated disease. The drug also restored venetoclax sensitivity in resistant AML models.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
Multiple myeloma immunotherapies like bispecific antibodies and CAR-T cells show high response rates and prolonged survival, but access is hindered by the need for initial hospital stays for bispecifics. Research indicates mezigdomide can reverse T cell exhaustion to boost these therapies, while longer-term CARVYKTI data show significant survival benefits.
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
Presenters at the 2026 ICE-T Conference discussed the growing role of bispecific antibodies and CAR T-cell therapies in hematologic cancers, while a separate study found that structural instability of linkers in symmetric bispecific antibodies could pose manufacturing hurdles.
Sponsors are adopting AI-enabled tools, integrated operating models and decentralized designs to accelerate clinical trials. FDA and EMA guidance underscores sponsor accountability, while new modeling links integrated operations to higher program value.
A new antibody-drug conjugate targeting IL1RAP has shown potent preclinical activity against Ewing sarcoma and other fusion-driven cancers, with minimal off-target toxicity. Researchers at UBC report tumor eradication and reduced metastasis, with clinical trials being planned.
The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
CO-005, a humanized anti-CD47 fusion protein from Caedo Oncology, showed potent antitumor activity in preclinical models of B-cell lymphoma, including rituximab-resistant tumors. The therapy induces programmed cancer cell death while disrupting immune checkpoints, offering a potential solution to CD20 resistance.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779018 |
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy |
RECRUITING | PHASE2 |
| NCT07763054 |
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients |
RECRUITING | |
| NCT07739849 |
Flow on FNA/Core Project- Faster Diagnosis for Lymphoma: Utilising Flow Cytometry on FNA Samples of Lymph Nodes to Diagnose Lymphoma in Hours, Not Days. |
NOT_YET_RECRUITING | NA |
| NCT07714044 |
Rutgers University Study of the Genetics of Blood Cancers |
NOT_YET_RECRUITING | |
| NCT07711483 |
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07705178 |
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL) |
RECRUITING | NA |
| NCT07698080 |
Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07696169 |
Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers |
NOT_YET_RECRUITING | |
| NCT07654426 |
The CARDIOPROTECT Trial |
RECRUITING | PHASE2 |
| NCT07628634 |
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors |
RECRUITING | EARLY_PHASE1 |
